Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

被引：0

作者：

Zelniker, T. A. ^{[1
,2
]}

Raz, I. ^{[3
]}

Mosenzon, O. ^{[3
]}

Dwyer, J. P. ^{[4
]}

Heerspink, H. J. L. ^{[5
]}

Cahn, A. ^{[3
]}

Im, K. ^{[1
,2
]}

Bhatt, D. L. ^{[1
,2
]}

Leiter, L. A. ^{[6
]}

McGuire, D. K. ^{[7
]}

Wilding, J. P. H. ^{[8
]}

Gause-Nilsson, I. A. M. ^{[9
]}

Langkilde, A. M. ^{[9
]}

Sabatine, M. S. ^{[1
,2
]}

Wiviott, S. D. ^{[1
,2
]}

机构：

[1] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Hadassah Univ, Med Ctr, Jerusalem, Israel

[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA

[5] Univ Med Ctr Groningen, Groningen, Netherlands

[6] Univ Toronto, Toronto, ON, Canada

[7] Univ Texas Southwestern Med Sch, Dallas, TX USA

[8] Univ Liverpool, Liverpool, Merseyside, England

[9] AstraZeneca, Gothenburg, Sweden

来源：

EUROPEAN HEART JOURNAL | 2019年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

192

引用

页码：54 / 54

页数：1

共 50 条

[1] Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Zelniker, T.
Raz, I.
Mosenzon, O.
Dwyer, J.
Heerspink, H.
Cahn, A.
Im, K.
Deepak, B.
Leiter, L.
McGuire, D.
Wilding, J.
Gause-Nilsson, I.
Langkilde, A. M.
Sabatine, M.
Wiviott, S.
WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S175 - S175
[2] Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
Oyama, Kazuma
Raz, Itamar
Cahn, Avivit
Kuder, Julia
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Park, Kyong-Soo
Goudev, Assen
Diaz, Rafael
Spinar, Jindrich
Gause-Nilsson, Ingrid A. M.
Mosenzon, Ofri
Sabatine, Marc S.
Wiviott, Stephen D.
EUROPEAN HEART JOURNAL, 2022, 43 (31) : 2958 - 2967
[3] Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
Zelniker, Thomas A.
Bonaca, Marc P.
Furtado, Remo H. M.
Mosenzon, Ofri
Kuder, Julia F.
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Budaj, Andrzej
Kiss, Robert G.
Padilla, Francisco
Gause-Nilsson, Ingrid
Langkilde, Anna Maria
Raz, Itamar
Sabatine, Marc S.
Wiviott, Stephen D.
CIRCULATION, 2020, 141 (15) : 1227 - 1234
[4] The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbAlc: Analyses from DECLARE-TIMI 58
Cahn, Avivit
Wiviott, Stephen D.
Mosenzon, Ofri
Murphy, Sabina
Goodrich, Erica L.
Bhatt, Deepak L.
Leiter, Lawrence A.
Mcguire, Darren K.
Wilding, John
Gause-Nilsson, Ingrid A.
Langkilde, Anna Maria
Sabatine, Marc S.
Raz, Itamar
DIABETES, 2021, 70
[5] Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
Kolkailah, Ahmed A.
Wiviott, Stephen D.
Raz, Itamar
Murphy, Sabina A.
Mosenzon, Ofri
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John P. H.
Gause-Nilsson, Ingrid
Sabatine, Marc S.
McGuire, Darren K.
DIABETES CARE, 2022, 45 (02) : E27 - E29
[6] Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
Furtado, Remo H. M.
Raz, Itamar
Goodrich, Erica L.
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Aylward, Philip
Dalby, Anthony J.
Dellborg, Mikael
Dimulescu, Doina
Nicolau, Jose C.
Oude Ophuis, Anthonius J. M.
Cahn, Avivit
Mosenzon, Ofri
Gause-Nilsson, Ingrid
Langkilde, Anna Maria
Sabatine, Marc S.
Wiviott, Stephen D.
CIRCULATION, 2022, 145 (21) : 1581 - 1591
[7] Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
Oyama, Kazuma
Wiviott, Stephen D.
Raz, Itamar
Cahn, Avivit
Goodrich, Erica
Bhatt, Deepak L.
Leiter, Lawrence
McGuire, Darren K.
Wilding, John
Gause-Nilsson, Ingrid A.
Mosenzon, Ofri
Sabatine, Marc S.
Bohula, Erin A.
CIRCULATION, 2020, 142
[8] Effect of dapagliflozin on atrial fibrillation/flutter in patients with Type 2 Diabetes mellitus: insights from the DECLARE-TIMI 58 trial
Zelniker, T.
Bonaca, M.
Mosenzon, O.
Kuder, J.
Murphy, S.
Remo, F.
Deepak, B.
Leiter, L.
McGuire, D.
Wilding, J.
Budaj, A.
Kiss, G.
Padilla, F.
Gause-Nilsson, I.
Langkilde, A. M.
Raz, I.
Sabatine, M.
Wiviott, S.
WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S158 - S158
[9] Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
Zelniker, Thomas A.
Bonaca, Marc P.
Mosenzon, Ofri
Kuder, Julia F.
Murphy, Sabina A.
Furtado, Remo H.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P.
Budaj, Andrzej
Kiss, Robert Gabor
Padilla, Francisco
Gause-Nilsson, Ingrid A.
Langkilde, Anna Maria
Raz, Itamar
Sabatine, Marc S.
Wiviott, Stephen D.
CIRCULATION, 2019, 140
[10] Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
Furtado, Remo H. M.
Bonaca, Marc P.
Raz, Itamar
Zelniker, Thomas A.
Mosenzon, Ofri
Cahn, Avivit
Kuder, Julia
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Ruff, Christian T.
Nicolau, Jose C.
Gause-Nilsson, Ingrid A. M.
Fredriksson, Martin
Langkilde, Anna Maria
Sabatine, Marc S.
Wiviott, Stephen D.
CIRCULATION, 2019, 139 (22) : 2516 - 2527

← 1 2 3 4 5 →